I2Pure is excited to announce a patent pending milestone achievement in iodine technology. Known for its expertise in iodine science and innovation, I2Pure has developed a novel and proprietary methodology to infuse nano particles with iodine that results in shelf-stable, pH-neutral iodine solutions. Using this technology, the efficacy of existing iodine products can be improved, and new iodine products can be developed that were previously out-of-reach to science and medicine. I2Pure’s breakthrough process is environmentally friendly, non-toxic, and cost-effective, consuming a fraction of the energy previously required to combine iodine with nano materials.
The new methodology enables the delivery of precise levels of iodine in products that can be stored at room temperature and are inherently sterile. Many resulting iodine formulations will satisfy existing FDA drug monographs while making available higher concentrations of free iodine, the antimicrobial natural element that global healthcare relies upon. For example, I2Pure’s proprietary solution will eliminate the need for surgeons and other medical professionals to mix their own iodine formulations in the operating room or other treatment areas.
“I2Pure remains steadfast in our vision to revolutionize the delivery of high-potency molecular iodine to applications across healthcare and beyond,” said Jeff Jochims, I2Pure CEO. “This is a key milestone along our path. With this achievement, I2Pure can design more effective doses of iodine in a variety of pH-neutral applications. With formulations that meet existing FDA monographs, we envision rapid market entry of new iodine products, such as antisepsis solutions, wound irrigations, oral rinses, and numerous other products.”
Explained Jack Kessler, PhD, I2Pure’s Chief Scientific Officer and Board Member, “I’m incredibly proud of our team. Just consider povidone-iodine, a worldwide healthcare staple that has not seen a material enhancement in almost 70 years. That product delivers only 1-3 ppm of free iodine, the only antimicrobial portion of PVP-I. I2Pure’s achievement enables delivery of iodine formulations with hundreds of times more ppm of free iodine. It’s incredible!”
I2Pure remains actively engaged in collaborations and product development efforts across many product categories. The company will soon introduce a line of over-the-counter products sold directly to consumers. The company is also progressing to seek regulatory approval of several healthcare products both independently and with strategic partners while also expanding its research and development efforts in other fields.
“We have under our roof three world-class iodine scientists in Drs. Ilker Bayer, Eugene Duan, and Jack Kessler, who together bring to I2Pure a combined expertise of more than 75 years in applied iodine technology. Their tireless effort to advance iodine science and product development in ways that improve the world is awe-inspiring,” concluded Jochims.
About I2Pure: I2Pure is a healthcare technology company dedicated to advancing the world of health and biosafety by preventing infections and disease through its patented, non-toxic molecular iodine platform. I2Pure’s mission is to prevent pathogenic threats to the world. Our technology can be used across virtually every facet of surgical and therapeutic interaction with human or animal tissue to prevent infection. The platform technology can be delivered via solutions, polymers and coatings and can be extended into medical devices, antisepsis, cosmetics, water safety, food safety and preservation, aquaculture and more.
For more information about I2Pure, visit https://www.i2pure.com or contact Abigail Moses at Abigail@i2pure.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912470767/en/
Contacts
Abigail Moses
Abigail@i2pure.com
